QRG Capital Management Inc. Purchases 18,251 Shares of Smith & Nephew SNATS, Inc. $SNN

QRG Capital Management Inc. raised its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 29.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,311 shares of the medical equipment provider’s stock after purchasing an additional 18,251 shares during the quarter. QRG Capital Management Inc.’s holdings in Smith & Nephew SNATS were worth $2,552,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Garner Asset Management Corp bought a new stake in shares of Smith & Nephew SNATS during the 4th quarter valued at $27,000. Arax Advisory Partners increased its stake in Smith & Nephew SNATS by 142.6% in the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 569 shares in the last quarter. Advisors Asset Management Inc. bought a new stake in Smith & Nephew SNATS during the fourth quarter valued at about $36,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Smith & Nephew SNATS in the third quarter valued at about $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Smith & Nephew SNATS in the fourth quarter valued at about $43,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Performance

Shares of SNN stock traded up $0.26 during trading hours on Tuesday, hitting $30.81. The stock had a trading volume of 150,580 shares, compared to its average volume of 1,075,069. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a one year low of $28.56 and a one year high of $38.79. The stock’s 50-day moving average price is $30.30 and its two-hundred day moving average price is $32.51.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Wall Street Zen upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Canaccord Genuity Group dropped their price target on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Weiss Ratings cut shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, June 11th. Finally, Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a report on Monday, May 11th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $30.93.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.